Key Points
- Verrica Pharmaceuticals CMO Noah Rosenberg purchased 4,200 shares at an average price of $4.91, investing $20,622 and increasing his direct ownership by 178.19% to 6,557 shares.
- VRCA opened at $4.68, with a market capitalization of approximately $80.4 million and a 12-month trading range of $3.28 to $9.82. Institutional investors own 42.45% of the company.
- Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $14.50; targets include HC Wainwright’s $12.00 “Buy” rating alongside sell and strong-sell recommendations.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) CMO Noah Rosenberg bought 4,200 shares of the stock in a transaction on Monday, August 17th. The stock was acquired at an average cost of $4.91 per share, for a total transaction of $20,622.00. Following the acquisition, the chief marketing officer directly owned 6,557 shares in the company, valued at approximately $32,194.87. The trade was a 178.19% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Verrica Pharmaceuticals Stock Performance
Shares of NASDAQ VRCA opened at $4.68 on Wednesday. Verrica Pharmaceuticals Inc. has a 12 month low of $3.28 and a 12 month high of $9.82. The company has a market cap of $80.40 million, a P/E ratio of -2.80 and a beta of 1.49. The business's 50 day moving average is $5.65 and its two-hundred day moving average is $5.92. The company has a quick ratio of 1.33, a current ratio of 1.45 and a debt-to-equity ratio of 0.18.
Institutional Trading of Verrica Pharmaceuticals
Several institutional investors have recently modified their holdings of the company. AQR Capital Management LLC increased its position in shares of Verrica Pharmaceuticals by 306.7% during the first quarter. AQR Capital Management LLC now owns 58,711 shares of the company's stock valued at $26,000 after purchasing an additional 44,275 shares during the period. Qube Research & Technologies Ltd acquired a new position in shares of Verrica Pharmaceuticals in the second quarter valued at $28,000. Invesco Ltd. lifted its position in Verrica Pharmaceuticals by 64.8% in the first quarter. Invesco Ltd. now owns 74,388 shares of the company's stock worth $33,000 after purchasing an additional 29,256 shares during the period. Bridgeway Capital Management LLC bought a new position in Verrica Pharmaceuticals in the third quarter worth $52,000. Finally, Goldman Sachs Group Inc. boosted its stake in Verrica Pharmaceuticals by 23.3% during the first quarter. Goldman Sachs Group Inc. now owns 139,055 shares of the company's stock worth $61,000 after buying an additional 26,308 shares in the last quarter. Institutional investors and hedge funds own 42.45% of the company's stock.
Analysts Set New Price Targets
VRCA has been the topic of a number of research reports. Zacks Research raised shares of Verrica Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Monday, May 11th. HC Wainwright assumed coverage on shares of Verrica Pharmaceuticals in a report on Tuesday, May 26th. They issued a "buy" rating and a $12.00 price target for the company. Wall Street Zen downgraded shares of Verrica Pharmaceuticals from a "sell" rating to a "strong sell" rating in a report on Saturday. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, July 15th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $14.50.
Read Our Latest Stock Analysis on VRCA
Verrica Pharmaceuticals Company Profile
(
Get Free Report)
Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica's approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.
Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
